html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 12 VPA, lithium, amiodarone, and other non-DA Michael R. Silver and Stewart A. Factor Introduction Considering that the characteristic motor features of Parkinson’s disease (PD)…
Figure 11.1 Management of motor complications in Parkinson’s disease 1. Glutamate receptor antagonists Abnormalities in the thalamo- and cortico-striatal glutamatergic transmission have long been implicated in the pathogenesis of LIDs….
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 10 Medication-induced tremors Peter A. LeWitt Tremor, a regular to-and-fro movement generated by the uniform repeated activations of lower motor units, is a characteristic manifestation…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 9 Restless legs syndrome Roongroj Bhidayasiri and Pattamon Panyakaew Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a sensorimotor disorder with a primary…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 8 Atypical antipsychotics and movement disorders Rob M.A. de Bie Introduction The term atypical antipsychotics alludes to the existence of a class of drugs which…
Figure 1.1 Schematic proposal of pathways comparing normal (A) to akathisia (B). Reduced dopaminergic stimulation from the ventral tegmental area (VTA) may create unopposed stimulation of the pathway from the…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 4 Serotonin syndrome Dimitrios A. Nacopoulos and Hubert H. Fernandez Introduction Serotonin syndrome, a medical condition that gained prominent attention with the death of Libby…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 7 Tardive dyskinesia treatment Tracy M. Jones, Israt Jahan, and Theresa A. Zesiewicz Introduction Tardive syndromes (TS) are characterized by abnormal, involuntary movements, and are…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 2 Acute dystonia Anne Marthe Meppelink and Mark J. Edwards Introduction Movement disorders can occur as a side effect of many different pharmacological agents, including…
Figure 3.1: Flow chart of treatment options in patients with neuroleptic malignant syndrome (NMS). PO=per os, NG=nasogastric tube, bd=bis in die (twice per day), qds=quaque die (four times per day),…
